|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6046
|
|
pubmed:dateCreated |
1977-1-29
|
|
pubmed:abstractText |
Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73% and 76% for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (medium 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trial of chemoimmunotherapy of breast cancer should be carried out.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-1063907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-1105174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-1203853,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-1246307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-13040490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-14341275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4122562,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4140327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4366760,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4413764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4471223,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-4851001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-5448777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-55529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/791447-58143
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-1447
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1222-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:791447-Adult,
pubmed-meshheading:791447-Aged,
pubmed-meshheading:791447-BCG Vaccine,
pubmed-meshheading:791447-Breast Neoplasms,
pubmed-meshheading:791447-Clinical Trials as Topic,
pubmed-meshheading:791447-Cyclophosphamide,
pubmed-meshheading:791447-Doxorubicin,
pubmed-meshheading:791447-Drug Therapy, Combination,
pubmed-meshheading:791447-Female,
pubmed-meshheading:791447-Fluorouracil,
pubmed-meshheading:791447-Humans,
pubmed-meshheading:791447-Middle Aged,
pubmed-meshheading:791447-Neoplasm Metastasis,
pubmed-meshheading:791447-Remission, Spontaneous,
pubmed-meshheading:791447-Time Factors
|
|
pubmed:year |
1976
|
|
pubmed:articleTitle |
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
